Skip to main content

Table 2 Risk estimation based on the distributions of genotype and allele frequency

From: High-resolution melting analysis reveals genetic polymorphisms in MicroRNAs confer hepatocellular carcinoma risk in Chinese patients

microRNA

Model

Genotype

Controls n (%)

HCCs n (%)

AORa(95% CI)

P

AIC

BIC

miR-196a2

Codominant

TT

121 (29.8)

60 (19.1)

1.00

7e-04

980.3

1003.2

  

CT

214 (52.7)

209 (66.6)

1.95 (1.36-2.81)

   
  

CC

71 (17.5)

45 (14.3)

1.28 (0.79-2.08)

   
 

Dominant

TT

121 (29.8)

60 (19.1)

1.00

0.0011

982.3

1000.7

  

CT + CC

285 (70.2)

254 (80.9)

1.79 (1.25-2.54)

   
 

Recessive

TT + CT

335 (82.5)

269 (85.7)

1.00

0.26

991.8

1010.1

  

CC

71 (17.5)

45 (14.3)

0.79 (0.53-1.19)

   
 

Overdominant

TT + CC

192 (47.3)

105 (33.4)

1.00

2e-04

979.3

997.6

  

CT

214 (52.7)

209 (66.6)

1.77 (1.31-2.41)

   
 

Addictive

   

1.20 (0.95-1.52)

0.12

990.6

1008.9

 

Allele

T

457 (56.0)

329 (52.0)

1.00

0.156

  
  

C

357 (44.0)

299 (48.0)

1.16 (0.94-1.43)

   

miR-499

Codominant

TT

301 (74.1)

195 (62.1)

1.00

0.0015

982.1

1005

  

CT

101 (24.9)

117 (37.3)

1.79 (1.30-2.47)

   
  

CC

4 (1)

2 (0.6)

0.73 (0.13-4.06)

   
 

Dominant

TT

301 (74.1)

195 (62.1)

1.00

6e-04

981.2

999.5

  

CT + CC

105 (25.9)

119 (37.9)

1.75 (1.27-2.40)

   
 

Recessive

TT + CT

402 (99.0)

312 (99.4)

1.00

0.57

992.7

1011

  

CC

4 (1.0)

2 (0.6)

0.61 (0.11-3.38)

   
 

Overdominant

TT + CC

305 (75.1)

197 (62.7)

1.00

3e-04

980.2

998.5

  

CT

101 (24.9)

117 (37.3)

1.80 (1.30-2.48)

   
 

Addictive

   

1.64 (1.21-2.23)

0.0014

982.9

1001.2

 

Allele

T

704 (86.0)

507 (81.0)

1.00

0.003

  
  

C

110 (14.0)

121 (19.0)

1.53 (1.15-2.03)

   

miR-146a

Codominant

CC

159 (39.2)

149 (47.5)

1.00

0.017

986.8

1009.7

  

CG

244 (60.1)

165 (52.5)

0.71 (0.53-0.96)

   
  

GG

3 (0.7)

0 (0)

0.00 (0.00-NA)

   
 

Dominant

CC

159 (39.2)

149 (47.5)

1.00

0.02

987.6

1005.9

  

CG + GG

247 (60.8)

165 (52.5)

0.70 (0.52-0.95)

   
 

Recessive

CC + CG

403 (99.3)

314 (100)

1.00

0.074

989.8

1008.2

  

GG

3 (0.7)

0 (0.0)

0.00 (0.00-NA)

   
 

Overdominant

CC + GG

162 (39.9)

149 (47.5)

1.00

0.033

988.5

1006.8

  

CG

244 (60.1)

165 (52.5)

0.72 (0.54-0.97)

   
 

Addictive

   

0.69 (0.51-0.93)

0.013

986.9

1005.2

 

Allele

C

564 (69.0)

463 (74.0)

1.00

0.065

  
  

G

250 (31.0)

165 (26.0)

0.80 (0.64-1.01)

   

miR-301b

Codominant

AA

319 (78.6)

248 (79.0)

1.00

0.96

994.9

1017.8

  

AG

85 (20.9)

65 (20.7)

1.00 (0.69-1.43)

   
  

GG

2 (0.5)

1 (0.3)

0.70 (0.06-7.78)

   
 

Dominant

AA

319 (78.6)

248 (79.0)

1.00

0.95

993

1011.3

  

AG + GG

87 (21.4)

66 (21.0)

0.99 (0.69-1.42)

   
 

Recessive

AA + AG

404 (99.5)

313 (99.7)

1.00

0.77

992.9

1011.3

  

GG

2 (0.5)

1 (0.3)

0.70 (0.06-7.78)

   
 

Overdominant

AA + GG

321 (79.1)

249 (79.3)

1.00

0.99

993

1011.3

  

AG

85 (20.9)

65 (20.7)

1.00 (0.69-1.44)

   
 

Addictive

   

0.98 (0.69-1.40)

0.92

993

1011.3

 

Allele

A

725 (89.0)

561 (89.0)

1.00

0.872

  
  

G

89 (11.0)

67 (11.0)

0.97 (0.70-1.36)

   
  1. HCC, hepatocellular carcinoma; AOR, adjusted odds ratio; CI, confidence interval; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion.
  2. NA, not available.
  3. aAdjusted for age and sex.